References
- Insel TR. Rethinking schizophrenia. Nature468(7321), 187–193 (2010).
- Puri BK. Progressive structural brain changes in schizophrenia. Expert Rev. Neurother.10(1), 33–42 (2010).
- Taylor S, Christensen JD, Holcomb JM, Garver DL. Volume increases in striatum associated with positive symptom reduction in schizophrenia: a preliminary observation. Psychiatry Res.140(1), 85–89 (2005).
- Thompson PM, Bartzokis G, Hayashi KM et al. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cereb. Cortex19(5), 1107–1123 (2009).
- Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr. Bull.34(2), 354–366 (2008).
- Smieskova R, Fusar-Poli P, Allen P et al. The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia? – A systematic review. Curr. Pharm. Des.15(22), 2535–2549 (2009).
- Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry68(2), 128–137 (2011).
- Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology30(9), 1649–1661 (2005).
- Konopaske GT, Dorph-Petersen KA, Pierri JN, Wu Q, Sampson AR, Lewis DA. Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology32(6), 1216–1223 (2007).
- Konopaske GT, Dorph-Petersen KA, Sweet RA et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol. Psychiatry63(8), 759–765 (2008).
- Harrison PJ, Lewis DA. Neuropathology of schizophrenia. In: Schizophrenia, 2nd Edition. Hirsch SR, Weinberger DR (Eds). Blackwell Science, Oxford, UK, 310–325 (2003).
- Lewis DA. Antipsychotic medications and brain volume: do we have cause for concern? Arch. Gen. Psychiatry68(2), 126–127 (2011).
- Sweet RA, Henteleff RA, Zhang W, Sampson AR, Lewis DA. Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. Neuropsychopharmacology34(2), 374–389 (2009).
- Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry67(3), 255–262 (2010).
- Davis JM. Dose equivalence of the antipsychotic drugs. J. Psychiatr. Res.11, 65–69 (1974).
- Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry33(6), 766–771 (1976).
- Gogtay N, Giedd JN, Lusk L et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc. Natl Acad. Sci. USA101(21), 8174–8179 (2004).
- Abbott A. Schizophrenia: the drug deadlock. Nature468(7321), 158–159 (2010).
- Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353(12), 1209–1223 (2005).
- Wykes T. Cognitive remediation therapy needs funding. Nature468(7321), 165–166 (2010).